1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
2
|
Balata H, Fong KM, Hendriks LE, Lam S,
Ostroff JS, Peled N, Wu N and Aggarwal C: Prevention and early
detection for NSCLC: Advances in Thoracic Oncology 2018. J Thorac
Oncol. 14:1513–1527. 2019. View Article : Google Scholar : PubMed/NCBI
|
3
|
Rodriguez-Lara V, Hernandez-Martinez JM
and Arrieta O: Influence of estrogen in non-small cell lung cancer
and its clinical implications. J Thorac Dis. 10:482–497. 2018.
View Article : Google Scholar : PubMed/NCBI
|
4
|
Schiller JH, Harrington D, Belani CP,
Langer C, Sandler A, Krook J, Zhu J and Johnson DH; Eastern
Cooperative Oncology Group, : Comparison of four chemotherapy
regimens for advanced non-small-cell lung cancer. N Engl J Med.
346:92–98. 2002. View Article : Google Scholar : PubMed/NCBI
|
5
|
Li HD and Liu SL: Molecular targeted
therapy for non-small cell lung cancer: The reality in China and
coping strategy. Prac J Med Pharm. 35:373–379. 2018.
|
6
|
Burkhard P and Stetefeld J: Coiled coils:
A highly versatile protein folding motif. Trends Cell Biol.
11:82–88. 2001. View Article : Google Scholar : PubMed/NCBI
|
7
|
Yin DT, Xu J, Lei M, Li H, Wang Y, Liu Z,
Zhou Y and Xing M: Characterization of the novel tumor-suppressor
gene CCDC67 in papillary thyroid carcinoma. Oncotarget.
7:5830–5841. 2016. View Article : Google Scholar : PubMed/NCBI
|
8
|
Pangeni RP, Channathodiyil P, Huen DS,
Eagles LW, Johal BK, Pasha D, Hadjistephanou N, Nevell O, Davies
CL, Adewumi AI, et al: The GALNT9, BNC1 and CCDC8 genes are
frequently epigenetically dysregulated in breast tumours that
metastasise to the brain. Clin Epigenetics. 7:572015. View Article : Google Scholar : PubMed/NCBI
|
9
|
Gong Y, Qiu W, Ning X, Yang X, Liu L, Wang
Z, Lin J, Li X and Guo Y: CCDC34 is up-regulated in bladder cancer
and regulates bladder cancer cell proliferation, apoptosis and
migration. Oncotarget. 6:25856–25867. 2015. View Article : Google Scholar : PubMed/NCBI
|
10
|
Hu DD, Li PC, He YF, Jia W and Hu B:
Overexpression of coiled-coil domain-containing protein 34 (CCDC34)
and its correlation with angiogenesis in esophageal squamous cell
carcinoma. Med Sci Monit. 24:698–705. 2018. View Article : Google Scholar : PubMed/NCBI
|
11
|
Sheffer M, Bacolod MD, Zuk O, Giardina SF,
Pincas H, Barany F, Paty PB, Gerald WL, Notterman DA and Domany E:
Association of survival and disease progression with chromosomal
instability: A genomic exploration of colorectal cancer. Proc Natl
Acad Sci USA. 106:7131–7136. 2009. View Article : Google Scholar : PubMed/NCBI
|
12
|
Radulovich N, Leung L, Ibrahimov E, Navab
R, Sakashita S, Zhu CQ, Kaufman E, Lockwood WW, Thu KL, Fedyshyn Y,
et al: Coiled-coil domain containing 68 (CCDC68) demonstrates a
tumor-suppressive role in pancreatic ductal adenocarcinoma.
Oncogene. 34:4238–4247. 2015. View Article : Google Scholar : PubMed/NCBI
|
13
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
14
|
Gazdar AF, Girard L, Lockwood WW, Lam WL
and Minna JD: Lung cancer cell lines as tools for biomedical
discovery and research. J Natl Cancer Inst. 102:1310–1321. 2010.
View Article : Google Scholar : PubMed/NCBI
|
15
|
Pan Y, Liu G, Zhou F, Su B and Li Y: DNA
methylation profiles in cancer diagnosis and therapeutics. Clin Exp
Med. 18:1–14. 2018. View Article : Google Scholar : PubMed/NCBI
|
16
|
Suurmeijer AJH, Kao YC and Antonescu CR:
New advances in the molecular classification of pediatric
mesenchymal tumors. Genes Chromosomes Cancer. 58:100–110. 2019.
View Article : Google Scholar : PubMed/NCBI
|
17
|
Kalemkerian GP, Narula N, Kennedy EB,
Biermann WA, Donington J, Leighl NB, Lew M, Pantelas J, Ramalingam
SS, Reck M, et al: Molecular testing guideline for the selection of
patients with lung cancer for treatment with targeted tyrosine
kinase inhibitors: American Society of Clinical Oncology
endorsement of the College of American Pathologists/International
Association for the Study of Lung Cancer/Association for Molecular
Pathology clinical practice guideline update. J Clin Oncol.
36:911–919. 2018. View Article : Google Scholar : PubMed/NCBI
|
18
|
Roeper J and Griesinger F: Epidermal
growth factor receptor tyrosine kinase inhibitors in advanced
nonsmall cell lung cancer: What is the preferred first-line
therapy? Curr Opin Oncol. 31:1–7. 2019. View Article : Google Scholar : PubMed/NCBI
|
19
|
Pirker R and Filipits M: From crizotinib
to lorlatinib: Continuous improvement in precision treatment of
ALK-positive non-small cell lung cancer. ESMO Open. 4:e0005482019.
View Article : Google Scholar : PubMed/NCBI
|
20
|
Liu S, Yang H, Jang Y, Zhang T, Yan R and
Zhang J: Evolution strategy of ROS1 kinase inhibitors for use in
cancer therapy. Future Med Chem. 10:1705–1720. 2018. View Article : Google Scholar : PubMed/NCBI
|
21
|
Rocco D, Della Gravara L and Battiloro C:
The role of combination chemo-immunotherapy in advanced non-small
cell lung cancer. Expert Rev Anticancer Ther. 19:561–568. 2019.
View Article : Google Scholar : PubMed/NCBI
|
22
|
Mcfarlane AA, Orriss GL and Stetefeld J:
The use of coiled-coil proteins in drug delivery systems. Eur J
Pharmacol. 625:101–107. 2009. View Article : Google Scholar : PubMed/NCBI
|
23
|
Frezzo JA and Montclare JK: Exploring the
potential of engineered coiled-coil protein microfibers in drug
delivery. Ther Deliv. 6:643–646. 2015. View Article : Google Scholar : PubMed/NCBI
|
24
|
Zhong J, Zhao M, Luo Q, Ma Y, Liu J, Wang
J, Yang M, Yuan X, Sang J and Huang C: CCDC134 is down-regulated in
gastric cancer and its silencing promotes cell migration and
invasion of GES-1 and AGS cells via the MAPK pathway. Mol Cell
Biochem. 372:1–8. 2013. View Article : Google Scholar : PubMed/NCBI
|
25
|
Tsolakis AV, Grimelius L and Islam MS:
Expression of the coiled coil domain containing protein 116 in the
pancreatic islets and endocrine pancreatic tumors. Islets.
4:349–353. 2012. View Article : Google Scholar : PubMed/NCBI
|
26
|
Wang Y, Liu Z, Luo R and Xie Y: Decreased
CCDC19 is correlated with unfavorable outcome in lung squamous cell
carcinoma. Int J Clin Exp Pathol. 11:802–807. 2018.PubMed/NCBI
|
27
|
Liu Z, Mai C, Yang H, Zhen Y, Yu X, Hua S,
Wu Q, Jiang Q, Zhang Y, Song X and Fang W: Candidate tumour
suppressor CCDC19 regulates miR-184 direct targeting of C-Myc
thereby suppressing cell growth in non-small cell lung cancers. J
Cell Mol Med. 18:1667–1679. 2014. View Article : Google Scholar : PubMed/NCBI
|
28
|
Cerrato A, Morra F, Di Domenico I and
Celetti A: NSCLC mutated isoforms of CCDC6 affect the intracellular
distribution of the wild type protein promoting cisplatinum
resistance and PARP inhibitors sensitivity in lung cancer cells.
Cancers (Basel). 12:442019. View Article : Google Scholar
|
29
|
Zhang X, Zheng Q, Wang C, Zhou H, Jiang G,
Miao Y, Zhang Y, Liu Y, Li Q, Qiu X and Wang E: CCDC106 promotes
non-small cell lung cancer cell proliferation. Oncotarget.
8:26662–26670. 2017. View Article : Google Scholar : PubMed/NCBI
|
30
|
Dana H, Chalbatani GM, Mahmoodzadeh H,
Karimloo R, Rezaiean O, Moradzadeh A, Mehmandoost N, Moazzen F,
Mazraeh A, Marmari V, et al: Molecular mechanisms and biological
functions of siRNA. Int J Biomed Sci. 13:48–57. 2017.PubMed/NCBI
|
31
|
Jain S, Pathak K and Vaidya A: Molecular
therapy using siRNA: Recent trends and advances of multi target
inhibition of cancer growth. Int J Biol Macromol. 116:880–892.
2018. View Article : Google Scholar : PubMed/NCBI
|
32
|
Ning Y, Wang C, Liu X, Du Y, Liu S, Liu K,
Zhou J and Zhou C: CK2-mediated CCDC106 phosphorylation is required
for p53 degradation in cancer progression. J Exp Clin Cancer Res.
38:1312019. View Article : Google Scholar : PubMed/NCBI
|
33
|
Liu Z, Li X, He X, Jiang Q, Xie S, Yu X,
Zhen Y, Xiao G, Yao K and Fang W: Decreased expression of updated
NESG1 in nasopharyngeal carcinoma: Its potential role and
preliminarily functional mechanism. Int J Cancer. 128:2562–2571.
2011. View Article : Google Scholar : PubMed/NCBI
|
34
|
Morra F, Merolla F, D'Abbiero D, Ilardi G,
Campione S, Monaco R, Guggino G, Ambrosio F, Staibano S, Cerrato A,
et al: Analysis of CCDC6 as a novel biomarker for the clinical use
of PARP1 inhibitors in malignant pleural mesothelioma. Lung Cancer.
135:56–65. 2019. View Article : Google Scholar : PubMed/NCBI
|
35
|
Morra F, Merolla F, Criscuolo D, Insabato
L, Giannella R, Ilardi G, Cerrato A, Visconti R, Staibano S and
Celetti A: CCDC6 and USP7 expression levels suggest novel treatment
options in high-grade urothelial bladder cancer. J Exp Clin Cancer
Res. 8:902019. View Article : Google Scholar
|
36
|
Cerrato A, Visconti R and Celetti A: The
rationale for druggability of CCDC6- tyrosine kinase fusions in
lung cancer. Mol Cancer. 17:462018. View Article : Google Scholar : PubMed/NCBI
|
37
|
Laxmi A, Gupta P and Gupta J: CCDC6, a
gene product in fusion with different protoncogenes, as a potential
chemotherapeutic target. Cancer Biomark. 24:383–393. 2019.
View Article : Google Scholar : PubMed/NCBI
|
38
|
Liu LB, Huang J, Zhong JP, Ye GL, Xue L,
Zhou MH, Huang G and Li SJ: High expression of CCDC34 is associated
with poor survival in cervical cancer patients. Med Sci Monit.
24:8383–8390. 2018. View Article : Google Scholar : PubMed/NCBI
|
39
|
Lei YY, Wang WJ, Mei JH and Wang CL:
Mitogen-activated protein kinase signal transduction in solid
tumors. Asian Pac J Cancer Prev. 15:8539–8548. 2014. View Article : Google Scholar : PubMed/NCBI
|
40
|
Huang N, Xia Y, Zhang D, Wang S, Bao Y, He
R, Teng J and Chen J: Hierarchical assembly of centriole subdistal
appendages via centrosome binding proteins CCDC120 and CCDC68. Nat
Commun. 8:150572017. View Article : Google Scholar : PubMed/NCBI
|